Which of the following statements about thioguanine is true?

Which of the following statements about thioguanine is true?

• A. It is a hormonal agent
• B. It is associated with decreased appetite
• C. It can cause hepatoportal sclerosis
• D. It is cell cycle specific

Answer: (C)

Thioguanine is an antineoplastic medication classified as a purine analog. Its mechanism of action is to interfere with DNA synthesis by mimicking the natural purine base, guanine. While it has various side effects, the characteristic that aligns with the correct answer is its potential to cause hepatoportal sclerosis, a condition related to liver function and blood flow within the portal vein system. This is particularly relevant because thioguanine can lead to hepatic complications through its effects on cell metabolism and potentially induce sinusoidal obstruction syndrome. In contrast, thioguanine is not a hormonal agent; it does not work through hormonal pathways, and thus that statement is not accurate. While appetite changes may occur with many chemotherapeutic agents, attributing a specific causal relationship between thioguanine and decreased appetite is not sufficiently supported by evidence to be deemed true. Additionally, thioguanine is not classified as cell cycle specific but rather has effects during multiple stages of the cell cycle, contributing to its use in treating certain malignancies. Therefore, the correct statement about thioguanine pertains to its association with hepatoportal sclerosis, reflecting its impact on liver structure and function.

Thioguanine is an antineoplastic medication classified as a purine analog. Its mechanism of action is to interfere with DNA synthesis by mimicking the natural purine base, guanine. While it has various side effects, the characteristic that aligns with the correct answer is its potential to cause hepatoportal sclerosis, a condition related to liver function and blood flow within the portal vein system. This is particularly relevant because thioguanine can lead to hepatic complications through its effects on cell metabolism and potentially induce sinusoidal obstruction syndrome.

In contrast, thioguanine is not a hormonal agent; it does not work through hormonal pathways, and thus that statement is not accurate. While appetite changes may occur with many chemotherapeutic agents, attributing a specific causal relationship between thioguanine and decreased appetite is not sufficiently supported by evidence to be deemed true. Additionally, thioguanine is not classified as cell cycle specific but rather has effects during multiple stages of the cell cycle, contributing to its use in treating certain malignancies. Therefore, the correct statement about thioguanine pertains to its association with hepatoportal sclerosis, reflecting its impact on liver structure and function.